Mapp Biopharmaceutical, Inc. is working toward the development of a multipurpose prevention technology that can protect against sexually transmitted infections and provide effective contraception at the same time
MB66 is intended to block sexual transmission of genital herpes and HIV as a rapidly dissolving film that releases anti-viral monoclonal antibodies to the vaginal mucosa.
A consortium of investigators from universities and the pharmaceutical industry is evaluating MB66.
The Phase 1 safety trial is being conducted at The Miriam Hospital in Providence, Rhode Island. The safety and efficacy of MB66 will continue to be evaluated in large clinical trials (phases II and III) over the next several years.
Read the MB66 FAQ.